CROS NT launches CROScheck for ICH GCP E6(R2) Guidelines
CROS NT, a global CRO, announced CROScheck, a clinical trial solution to deliver sponsors the biometrics oversight needed to assess data integrity from multiple sites. By incorporating data management and statistical methodology along with technology, sponsors can take a modular or full risk-based approach.
The guidelines state that the ultimate responsibility for the quality and integrity of the trial data will always reside with the sponsor even if fully outsourced to a CRO.
"CROScheck brings together leading edge intellectual property, powerful technology and world class expertise to service a growing need across our customer base. It gives sponsors the necessary oversight and confidence to meet global regulatory requirements,” said Andrew MacGarvey, CEO of CROS NT. “Central monitoring is increasingly becoming a critical component of clinical studies. CROScheck will allow our customers to focus resources and budget in the most effective way," he added.